Actiza Pharmaceutical

Docetaxel Trihydrate (CAS No. 114977-28-5) is a chemotherapeutic agent used in the treatment of various cancers, including breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, and gastric cancer. As a taxane compound, Docetaxel works by inhibiting the disassembly of microtubules, thereby disrupting the cell division process and preventing cancer cell proliferation. It is a highly effective treatment option, often used in combination therapy with other chemotherapeutic agents for advanced-stage cancers.

Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.